The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
have macula-on or macula-off rhegmatogenous retinal detachment
are eligible for pneumatic retinopexy, with identifiable retinal breaks
are phakic or pseudo-phakic
have detachments not of a rhegmatogenous nature
currently have blood in the vitreous, corneal opacity, or other conditions which limit the view of peripheral retina
have evidence of intraocular inflammation (uveitis)
have a history of current condition of uncontrollable, elevated IOP or open-angle glaucoma
have breaks not conducive to a single procedure of pneumatic retinopexy treatment
have proliferative vitreoretinopathy of type C or D